Celator Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Celator Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013090
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Celator Pharmaceuticals Inc (Celator) is a clinical-stage biopharmaceutical company that develops and distributes therapies for treating cancer disease. The company’s products include cytarabine and daunorubicin liposomal formulation, irinotecan HCI and floxuridine and hydrophobic docetaxel prodrug nanoparticle formulation. Its proprietary technology platform, CombiPlex enables the rational design and rapid evaluation of optimized combinations, incorporating traditional chemotherapies and molecularly targeted agents to deliver enhanced anti-cancer activity. The current development pipeline includes novel, clinical-stage combination products and drug discovery programs based on the CombiPlex platform. Celator is headquartered in Ewing, New Jersey, the US.

Celator Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Celator Pharma Raises US$39 Million In Venture Financing 10
Celator Pharma Secures US$3 Million In Venture Financing 11
Partnerships 12
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 12
Celator Pharma Extends Research Agreement With Cephalon 13
Equity Offering 14
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 14
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 16
Acquisition 18
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 18
Celator Pharmaceuticals Inc – Key Competitors 20
Celator Pharmaceuticals Inc – Key Employees 21
Celator Pharmaceuticals Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
May 10, 2016: Celator Pharmaceuticals Announces First Quarter 2016 Financial Results and Business Update 23
Mar 21, 2016: Celator Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2015 Financial Results 24
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Celator Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Celator Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Celator Pharma Raises US$39 Million In Venture Financing 10
Celator Pharma Secures US$3 Million In Venture Financing 11
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 12
Celator Pharma Extends Research Agreement With Cephalon 13
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 14
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 16
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 18
Celator Pharmaceuticals Inc, Key Competitors 20
Celator Pharmaceuticals Inc, Key Employees 21
Celator Pharmaceuticals Inc, Subsidiaries 22

★海外企業調査レポート[Celator Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fuji Oil Holdings Inc.:戦略・SWOT・企業財務分析
    Fuji Oil Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Fuji Oil Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Personal Genome Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Personal Genome Diagnostics Inc (PGD) is a genomic solution provider. The company develops next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes. It provides a portfolio of regulated tissue-based and liquid biopsy genomic products for laborat …
  • Banca Monte dei Paschi di Siena SpA:企業のM&A・事業提携・投資動向
    Banca Monte dei Paschi di Siena SpA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Banca Monte dei Paschi di Siena SpA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on …
  • Virgin Money PLC:企業の戦略的SWOT分析
    Virgin Money PLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Vita 34 AG (V3V):製薬・医療:M&Aディール及び事業提携情報
    Summary Vita 34 AG (Vita 34), formerly Vita 34 International AG, is an umbilical cord blood bank that collects, prepares, processes, deposits, and stores stem cells from umbilical cord blood. The company's products comprise vitaplus, vitaplus25, vitaplus50, vitapluscordtissue, vitapluscordtissue25, …
  • Blue Cross and Blue Shield of Florida Inc:企業の戦略的SWOT分析
    Blue Cross and Blue Shield of Florida Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • WESCO International, Inc.:企業の戦略・SWOT・財務分析
    WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report Summary WESCO International, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Becton, Dickinson:企業のM&A・事業提携・投資動向
    Becton, Dickinson - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Becton, Dickinson Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Origin Energy Limited:企業の戦略・SWOT・財務情報
    Origin Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Origin Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • American Builders & Contractors Supply Co Inc:企業の戦略・SWOT・財務情報
    American Builders & Contractors Supply Co Inc - Strategy, SWOT and Corporate Finance Report Summary American Builders & Contractors Supply Co Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, opera …
  • Society for Worldwide Interbank Financial Telecommunication:企業の戦略的SWOT分析
    Society for Worldwide Interbank Financial Telecommunication - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, k …
  • Kadimastem Ltd (KDST):製薬・医療:M&Aディール及び事業提携情報
    Summary Kadimastem Ltd (Kadimastem) is a clinical stage biopharmaceutical company that develops industrial regenerative medicines to treat neuro-degenerative diseases. Its technology platform enables the manufacturing of islet-like endocrine cells (differentiated cells) and glia restricted progenito …
  • Hino Motors Ltd (7205):企業の財務・戦略的SWOT分析
    Hino Motors Ltd (7205) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Thales SA:企業のM&A・事業提携・投資動向
    Thales SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Thales SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capita …
  • Bunge North America Inc:企業の戦略・SWOT・財務情報
    Bunge North America Inc - Strategy, SWOT and Corporate Finance Report Summary Bunge North America Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • EWE AG:石油・ガス:M&Aディール及び事業提携情報
    Summary EWE AG (EWE) operates in energy, telecommunication and information technology businesses. The company is involved in generation and transmission of energy, gas storage and waste water treatment. EWE plans, builds and operates renewable power generation plants globally. The company operates c …
  • S&B Foods Inc.:戦略・SWOT・企業財務分析
    S&B Foods Inc. - Strategy, SWOT and Corporate Finance Report Summary S&B Foods Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Genentech Inc-製薬・医療分野:企業M&A・提携分析
    Summary Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that develops and markets medicines to address serious medical needs. Its clinical development pipeline includes alectinib and Erlotinib for metastatic non-small cell lung cancer; Anti-ST2 for ast …
  • Chesapeake Energy Corporation (CHK)-石油・ガス分野:企業M&A・提携分析
    Summary Chesapeake Energy Corporation (Chesapeake) is an upstream oil and gas company. The company explores develops and produces oil and gas from its assets. It has liquid operations in Eagle Ford Shale; the Utica Shale; the Granite Wash, Cleveland, Tonkawa and Mississippian Lime plays in the Anada …
  • NACHI-FUJIKOSHI CORP.:企業の戦略・SWOT・財務情報
    NACHI-FUJIKOSHI CORP. - Strategy, SWOT and Corporate Finance Report Summary NACHI-FUJIKOSHI CORP. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆